|
PE20040079A1
(es)
*
|
2002-04-03 |
2004-04-19 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
MXPA04012188A
(es)
|
2002-06-05 |
2005-07-25 |
Johnson & Johnson |
Derivados de bisindolil-maleimida como inhibidores de cinasa.
|
|
DE60323749D1
(de)
|
2002-06-05 |
2008-11-06 |
Janssen Pharmaceutica Nv |
Substituierte pyrroline als kinase inhibitoren
|
|
GB0303319D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
EP1670497A4
(en)
*
|
2003-09-16 |
2009-07-15 |
Garvan Inst Med Res |
METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM
|
|
US20070142401A1
(en)
*
|
2003-10-27 |
2007-06-21 |
Novartis Ag |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
|
AU2004289303A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Synta Pharmaceuticals, Corp. |
Fused heterocyclic compounds
|
|
BRPI0506939A
(pt)
*
|
2004-01-19 |
2007-06-12 |
Novartis Ag |
derivados de indolilmaleimida como inibidores de pkc
|
|
GB0401089D0
(en)
*
|
2004-01-19 |
2004-02-18 |
Novartis Ag |
Organic compounds
|
|
JP2007532506A
(ja)
*
|
2004-04-08 |
2007-11-15 |
ノバルティス アクチエンゲゼルシャフト |
自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤
|
|
GB0410713D0
(en)
|
2004-05-13 |
2004-06-16 |
Novartis Ag |
Organic compounds
|
|
US8008320B2
(en)
|
2004-12-08 |
2011-08-30 |
Johannes Gutenberg-Universitatis |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
|
GB0504203D0
(en)
*
|
2005-03-01 |
2005-04-06 |
Novartis Ag |
Organic compounds
|
|
GB0507918D0
(en)
|
2005-04-19 |
2005-05-25 |
Novartis Ag |
Organic compounds
|
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
AU2006268908A1
(en)
|
2005-07-11 |
2007-01-18 |
Novartis Ag |
Indolylmaleimide derivatives
|
|
TR201802449T4
(tr)
|
2005-10-26 |
2018-03-21 |
Novartis Ag |
Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
|
|
RU2487711C2
(ru)
|
2005-11-21 |
2013-07-20 |
Новартис Аг |
Лечение нейроэндокринных опухолей
|
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
GB0613162D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
|
CA2658835A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Novartis Ag |
Use of pkc inhibitors in ocular diseases
|
|
KR20090073231A
(ko)
|
2006-10-20 |
2009-07-02 |
노파르티스 아게 |
３-(１ｈ-인돌-３-일)-４-[２-(４-메틸-피페라진-１-일)-퀴나졸린-４-일]-피롤-２,５-디온의 결정 변체
|
|
JP2010512335A
(ja)
*
|
2006-12-07 |
2010-04-22 |
ノバルティス アーゲー |
移植におけるｐｋｃ阻害剤の使用
|
|
ES2410955T3
(es)
|
2006-12-19 |
2013-07-04 |
Novartis Ag |
Derivados de indolilmaleimida como inhibidores de la quinasa
|
|
EP2167493A1
(en)
*
|
2007-03-09 |
2010-03-31 |
Novartis AG |
Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
|
|
EP2468301A1
(en)
|
2007-05-29 |
2012-06-27 |
Novartis AG |
New indications for anti-IL-1-beta therapy
|
|
RU2010116351A
(ru)
|
2007-09-27 |
2012-05-20 |
Новартис АГ (CH) |
Мониторинг лекарственных средств
|
|
WO2009060035A1
(en)
|
2007-11-08 |
2009-05-14 |
Novartis Ag |
Gene expression signatures for chronic/sclerosing allograft nephropathy
|
|
JP5576290B2
(ja)
|
2007-12-05 |
2014-08-20 |
ヨハネス、グーテンベルク−ウニフェルジテート、マインツ |
白血病の管理における３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体の用途
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
RU2441000C2
(ru)
*
|
2009-11-27 |
2012-01-27 |
Общество с ограниченной ответственностью "Молекулярные Технологии" |
4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
|
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
|
CN102821759A
(zh)
|
2010-03-30 |
2012-12-12 |
诺华有限公司 |
用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
CN102153605B
(zh)
*
|
2011-03-02 |
2014-02-19 |
福建省微生物研究所 |
一种咪唑立宾的提纯方法
|
|
UY34072A
(es)
*
|
2011-05-17 |
2013-01-03 |
Novartis Ag |
Derivados sustituidos de indol
|
|
JP2014518256A
(ja)
|
2011-06-27 |
2014-07-28 |
ノバルティス アーゲー |
テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
|
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
|
KR20140058543A
(ko)
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
신규 피롤로 피리미딘 유도체
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US8846712B2
(en)
|
2011-09-12 |
2014-09-30 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013057711A1
(en)
|
2011-10-21 |
2013-04-25 |
Novartis Ag |
Quinazoline derivatives as pi3k modulators
|
|
US20140348848A1
(en)
|
2011-12-02 |
2014-11-27 |
Dhananjay Kaul |
Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
|
DK2790705T3
(en)
|
2011-12-15 |
2018-03-12 |
Novartis Ag |
Use of inhibitors of the activity or function of PI3K
|
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
EP2847191B1
(en)
|
2012-05-09 |
2016-06-15 |
Sanofi |
Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
|
|
US20150284364A1
(en)
|
2012-11-07 |
2015-10-08 |
Nicole Bieri |
Substituted indole derivatives
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
BR112015012497B1
(pt)
|
2012-11-29 |
2022-05-17 |
Novartis Ag |
Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
|
|
JP2016508962A
(ja)
*
|
2012-12-10 |
2016-03-24 |
セントジーン アーゲー |
ガンを予防および治療するためのマレイミド誘導体の使用
|
|
JP2016504299A
(ja)
*
|
2012-12-10 |
2016-02-12 |
セントジーン アーゲー |
白血病を予防および治療するためのマレイミド誘導体の使用
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
WO2014174478A1
(en)
|
2013-04-26 |
2014-10-30 |
Novartis Ag |
Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
|
|
US9657007B2
(en)
|
2013-09-22 |
2017-05-23 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
MX2016012574A
(es)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Compuestos heteroarilo sustituidos y metodos de uso.
|
|
EP3134397A1
(en)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
EP3146077A4
(en)
|
2014-05-22 |
2018-05-02 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
MX2018001903A
(es)
|
2015-08-14 |
2018-06-20 |
Novartis Ag |
Inhibidores de mdm2 para el tratamiento de melanoma uveal.
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
CN109414384A
(zh)
*
|
2016-02-03 |
2019-03-01 |
高德美研究及发展公司 |
新的双芳香基丙炔基化合物，包含该化合物的药物和化妆品组合物及其用途
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
WO2018175302A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Polymer conjugates targeting c-src with reduced exposure
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CN110551103B
(zh)
*
|
2018-05-30 |
2022-08-23 |
北京大学深圳研究生院 |
一种jak3选择性抑制剂
|
|
IL322315A
(en)
|
2019-05-14 |
2025-09-01 |
Provention Bio Inc |
Methods and preparations for preventing type 1 diabetes
|
|
BR112021023054A2
(pt)
|
2019-05-23 |
2022-03-29 |
Novartis Ag |
Formas cristalinas de um inibidor de btk
|
|
AU2021287998B2
(en)
|
2020-06-11 |
2026-03-12 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
CN120817930B
(zh)
*
|
2025-06-30 |
2026-03-31 |
湖南科技职业学院 |
吲哚马来酰亚胺衍生物及其应用
|